MiRNA landscape in stage i epithelial ovarian cancer defines the histotype specificities

Clinical Cancer Research

Volumn 19, Issue 15, 2013, Pages 4114-4123

  Calura, Enrica ^a   Fruscio, Robert ^b,d   Paracchini, Lara ^e   Bignotti, Eliana ^f   Ravaggi, Antonella ^f   Martini, Paolo ^a   Sales, Gabriele ^a   Beltrame, Luca ^e   Clivio, Luca ^e   Ceppi, Lorenzo ^b,d   Di Marino, Mariacristina ^e   Nerini, Ilaria Fuso ^e   Zanotti, Laura ^f   Cavalieri, Duccio ^h   Cattoretti, Giorgio ^c   Perego, Patrizia ^c   Milani, Rodolfo ^b,d   Katsaros, Dionyssios ^d,i   Tognon, Germana ^d,g   Sartori, Enrico ^g   Pecorelli, Sergio ^f,g   Mangioni, Costantino ^b,d   D'Incalci, Maurizio ^d,e   Romualdi, Chiara ^a   Marchini, Sergio ^e   more..

^a UNIVERSITY OF PADOVA   (Italy)

^b Div of Obstetrics and Gynecology   (Italy)

^c SAN GERARDO HOSPITAL   (Italy)

^d IRCCS   (Italy)

^e MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^f Institute of Molecular Medicine Angelo Nocivelli   (Italy)

^g UNIVERSITY OF BRESCIA   (Italy)

^h RESEARCH AND INNOVATION CENTRE   (Italy)

ⁱ UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MICRORNA; MICRORNA 192; MICRORNA 194; MICRORNA 30A; TRANSCRIPTION FACTOR E2F3; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CLEAR CELL CARCINOMA; COLLOID CARCINOMA; FEMALE; GENE CLUSTER; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC REGULATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MICROARRAY ANALYSIS; OVARY CARCINOMA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY; TUMOR BIOPSY; VALIDATION PROCESS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; NEOPLASM; OVARY TUMOR; PATHOLOGY; PROGNOSIS;

FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICROARRAY ANALYSIS; MICRORNAS; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84881258346     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0360     Document Type: Article

References (37)

1. Kurman RJ, Shih leM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory.AmJ Surg Pathol 2010;34:433-43.
2. Prat J. New insights into ovarian cancer pathology. Ann Oncol 2012;23 Suppl 10:x111-7.
3. Kobel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 2008;5:e232.
4. Iorio MV, Visone R, Leva GD, Donati V, Petrocca F, Casalini P, et al. MicroRNA signatures in human ovarian cancer. Cancer Res 2007;67: 8699-707.
5. Ventura A, Jacks T. MicroRNAs and cancer: short RNAs go a long way. Cell 2009;136:586-91.
6. Marchini S, Mariani P, Chiorino G, Marrazzo E, Bonomi R, Fruscio R, et al. Analysis of gene expression in early-stage ovarian cancer. Clin Cancer Res 2008;14:7850-60.
7. Marchini S, Cavalieri D, Fruscio R, Calura E, Garavaglia D, Nerini IF, et al. Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections. Lancet Oncol 2011;12:273-85.
8. Trimbos JB, Parmar M, Vergote I, Guthrie D, Bolis G, Colombo N, et al. International collaborative ovarian neoplasm trial 1 and adjuvant chemotherapy in ovarian neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 2003;95:105-12.
9. Bisognin A, Sales G, Coppe A, Bortoluzzi S, Romualdi C. MAGIA2: from miRNA and genes expression data integrative analysis to micro-RNA-transcription factor mixed regulatory circuits (2012 update). Nucleic Acids Res 2012;40:W13-21.
10. Sales G, Coppe A, Bisognin A, Biasiolo M, Bortoluzzi S, Romualdi C. MAGIA, a web-based tool for miRNA and Genes Integrated Analysis. Nucleic Acids Res 2010;38:W352-9.
11. Chan JK, Tian C, Monk BJ, Herzog T, Kapp DS, Bell J, et al. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study. Cancer 2008;112:2202-10.
12. Fruscio R, Corso S, Ceppi L, Garavaglia D, Garbi A, Floriani I, et al. Conservative management of early-stage epithelial ovarian cancer: results of a large retrospective series. Ann Oncol 2013;24:138-44.
13. Gadducci A, Cosio S, Zola P, Sostegni B, Fuso L, Sartori E. Prognostic factors and clinical outcome of patients with recurrent early-stage epithelial ovarian cancer: an Italian multicenter retrospective study. Int J Gynecol Cancer 2013;23:461-8.
14. Dong P, Kaneuchi M, Watari H, Hamada J, Sudo S, Ju J, et al. MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1. Mol Cancer 2011;10:99.
15. Zhu H, Wu H, Liu X, Li B, Chen Y, Ren X, et al. Regulation of autophagy by a beclin 1-targeted microRNA, miR-30a, in cancer cells. Autophagy 2009;5:816-23.
16. Kreuzaler P, Watson CJ. Killing a cancer: what are the alternatives? Nat Rev Cancer 2012;12:411-24.
17. Reimer D, Hubalek M, Riedle S, Skvortsov S, Erdel M, Concin N, et al. E2F3a is critically involved in epidermal growth factor receptor-directed proliferation in ovarian cancer. Cancer Res 2010;70:4613-23.
18. Reimer D, Hubalek M, Kiefel H, Riedle S, Skvortsov S, Erdel M, et al. Regulation of transcription factor E2F3a and its clinical relevance in ovarian cancer. Oncogene 2011;30:4038-49.
19. Lee H, Park CS, Deftereos G, Morihara J, Stern JE, Hawes SE, et al. MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features. World J Surg Oncol 2012;10:174.
20. Wyman SK, Parkin RK, Mitchell PS, Fritz BR, O'Briant K, Godwin AK, et al. Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PLoS ONE 2009;4:e5311.
21. Braun CJ, Zhang X, Savelyeva I, Wolff S, Moll UM, Schepeler T, et al. p53-responsive microRNAs 192 and 215 are capable of inducing cell cycle arrest. Cancer Res 2008;68:10094-104.
22. Hino K, Tsuchiya K, Fukao T, Kiga K, Okamoto R, Kanai T, et al. Inducible expression of microRNA-194 is regulated by HNF-1alpha during intestinal epithelial cell differentiation. RNA 2008;14:1433-42.
23. Ma L, Huang Y, Zhu W, Zhou S, Zhou J, Zeng F, et al. An integrated analysis of miRNA and mRNA expressions in non-small cell lung cancers. PLoS ONE 2011;6:e26502.
24. Meng Z, Fu X, Chen X, Zeng S, Tian Y, Jove R, et al. miR-194 is a marker of hepatic epithelial cells and suppresses metastasis of liver cancer cells in mice. Hepatology 2010;52:2148-57.
25. Song B, Wang Y, Kudo K, Gavin EJ, Xi Y, Ju J. miR-192 regulates dihydrofolate reductase and cellular proliferation through the p53-miRNA circuit. Clin Cancer Res 2008;14:8080-6.
26. Stehling O, Vashisht AA, Mascarenhas J, Jonsson ZO, Sharma T, Netz DJA, et al. MMS19 assembles iron-sulfur proteins required for DNA metabolism and genomic integrity. Science 2012;337:195-9.
27. Pichiorri F, Suh S-S, Rocci A, De Luca L, Taccioli C, Santhanam R, et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell 2010;18:367-81.
28. Feng S, Cong S, Zhang X, Bao X, Wang W, Li H, et al. MicroRNA-192 targeting retinoblastoma 1 inhibits cell proliferation and induces cell apoptosis in lung cancer cells. Nucleic Acids Res 2011;39:6669-78.
29. Yang S, Du J, Wang Z, Yan J, Yuan W, Zhang J, et al. Dual mechanism of deltaEF1 expression regulated by bone morphogenetic protein-6 in breast cancer. Int J Biochem Cell Biol 2009;41:853-61.
30. Liu J, Yu G, Zhao Y, Zhao D, Wang Y, Wang L, et al. REGg modulates p53 activity by regulating its cellular localization. J Cell Sci 2010;123:4076-84.
31. Nag A, Bagchi S, Raychaudhuri P. Cul4A physically associates with MDM2 and participates in the proteolysis of p53. Cancer Res 2004;64: 8152-5.
32. Kim JH, Yoon SY, Kim C-N, Joo JH, Moon SK, Choe IS, et al. The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins. Cancer Lett 2004;203:217-24.
33. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998;92:725-34.
34. Honig A, Weidler C,Hausler S, Krockenberger M, Buchholz S,Koster F, et al. Overexpression of polycomb protein BMI-1 in human specimens of breast, ovarian, endometrial and cervical cancer. Anticancer Res 2010;30:1559-64.
35. Zhang F, Sui L, Xin T. Correlations of BMI-1 expression and telomerase activity in ovarian cancer tissues. Exp Oncol 2008;30:70-4.
36. Kelemen LE, Kobel M. Mucinous carcinomas of the ovary and colorectum: different organ, same dilemma. Lancet Oncol 2011;12: 1071-80.
37. Alexandre J, Ray-Coquard I, Selle F, Floquet A, Cottu P, Weber B, et al. Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum-paclitaxel-based chemotherapy, the GINECO experience. Ann Oncol 2010;21:2377-81.